share_log

Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25

Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25

富国银行将Integra Lifesciences的评级下调至同等权重,将目标股价下调至25美元
Benzinga ·  05/07 08:43

Wells Fargo analyst Vik Chopra downgrades Integra Lifesciences (NASDAQ:IART) from Overweight to Equal-Weight and lowers the price target from $45 to $25.

富国银行分析师维克·乔普拉将Integra Lifesciences(纳斯达克股票代码:IART)的评级从增持下调至同等,并将目标股价从45美元下调至25美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发